Advertisement

Primary central nervous system lymphoma and glioblastoma: differentiation using dynamic susceptibility-contrast perfusion-weighted imaging, diffusion-weighted imaging, and 18F-fluorodeoxyglucose positron emission tomography

Published:December 11, 2014DOI:https://doi.org/10.1016/j.clinimag.2014.12.002

      Abstract

      Objective

      The objective was to evaluate diagnostic performance of dynamic susceptibility-contrast perfusion-weighted imaging, diffusion-weighted imaging, and 18F-fluorodeoxyglucose positron emission tomography in differentiating primary central nervous system lymphoma (PCNSL) and glioblastoma.

      Materials and methods

      Twenty-three glioblastomas and 11 PCNSLs were analyzed with uncorrected cerebral blood volume (CBV) ratio, fifth percentile value of cumulative apparent diffusion coefficient histogram (ADC5%), and maximum standardized uptake value (SUVmax) using regions of interest created semiautomatically on enhancing areas.

      Results

      Uncorrected CBV ratio was highly capable of differentiating PCNSL from glioblastoma, as well as SUVmax and ADC5%.

      Conclusions

      Uncorrected CBV ratio demonstrates high diagnostic performance comparable to SUVmax.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Imaging
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Olson JE
        • Janney CA
        • Rao RD
        • Cerhan JR
        • Kurtin PJ
        • Schiff D
        • Kaplan RS
        • O'Neill BP
        The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis.
        Cancer. 2002; 95: 1504-1510
        • Bhagavathi S
        • Wilson JD
        Primary central nervous system lymphoma.
        Arch Pathol Lab Med. 2008; 132: 1830-1834
        • Raoux D
        • Duband S
        • Forest F
        • Trombert B
        • Chambonniere ML
        • Dumollard JM
        • Khaddage A
        • Gentil-Perret A
        • Peoc'h M
        Primary central nervous system lymphoma: immunohistochemical profile and prognostic significance.
        Neuropathology. 2010; 30: 232-240
        • DeAngelis LM
        Brain tumors.
        N Engl J Med. 2001; 344: 114-123
        • Giese A
        • Westphal M
        Treatment of malignant glioma: a problem beyond the margins of resection.
        J Cancer Res Clin Oncol. 2001; 127: 217-225
        • Schultz CJ
        • Bovi J
        Current management of primary central nervous system lymphoma.
        Int J Radiat Oncol Biol Phys. 2010; 76: 666-678
        • Hartmann M
        • Heiland S
        • Harting I
        • Tronnier VM
        • Sommer C
        • Ludwig R
        • Sartor K
        Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging.
        Neurosci Lett. 2003; 338: 119-122
        • Calli C
        • Kitis O
        • Yunten N
        • Yurtseven T
        • Islekel S
        • Akalin T
        Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors.
        Eur J Radiol. 2006; 58: 394-403
        • Kickingereder P
        • Wiestler B
        • Sahm F
        • Heiland S
        • Roethke M
        • Schlemmer HP
        • Wick W
        • Bendszus M
        • Radbruch A
        Primary central nervous system lymphoma and atypical glioblastoma: multiparametric differentiation by using diffusion-, perfusion-, and susceptibility-weighted MR imaging.
        Radiology. 2014; 272: 843-850
        • Guo AC
        • Cummings TJ
        • Dash RC
        • Provenzale JM
        Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics.
        Radiology. 2002; 224: 177-183
        • Doskaliyev A
        • Yamasaki F
        • Ohtaki M
        • Kajiwara Y
        • Takeshima Y
        • Watanabe Y
        • Takayasu T
        • Amatya VJ
        • Akiyama Y
        • Sugiyama K
        • Kurisu K
        Lymphomas and glioblastomas: differences in the apparent diffusion coefficient evaluated with high b-value diffusion-weighted magnetic resonance imaging at 3T.
        Eur J Radiol. 2012; 81: 339-344
        • Kosaka N
        • Tsuchida T
        • Uematsu H
        • Kimura H
        • Okazawa H
        • Itoh H
        18F-FDG PET of common enhancing malignant brain tumors.
        AJR Am J Roentgenol. 2008; 190: W365-W369
        • Okada Y
        • Nihashi T
        • Fujii M
        • Kato K
        • Okochi Y
        • Ando Y
        • Yamashita M
        • Maesawa S
        • Takebayashi S
        • Wakabayashi T
        • Naganawa S
        Differentiation of newly diagnosed glioblastoma multiforme and intracranial diffuse large B-cell Lymphoma using (11)C-methionine and (18)F-FDG PET.
        Clin Nucl Med. 2012; 37: 843-849
        • Yamaguchi S
        • Hirata K
        • Kobayashi H
        • Shiga T
        • Manabe O
        • Kobayashi K
        • Motegi H
        • Terasaka S
        • Houkin K
        The diagnostic role of (18)F-FDG PET for primary central nervous system lymphoma.
        Ann Nucl Med. 2014; 28: 603-609
        • Makino K
        • Hirai T
        • Nakamura H
        • Murakami R
        • Kitajima M
        • Shigematsu Y
        • Nakashima R
        • Shiraishi S
        • Uetani H
        • Iwashita K
        • Akter M
        • Yamashita Y
        • Kuratsu J
        Does adding FDG-PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study.
        Ann Nucl Med. 2011; 25: 432-438
        • Matsushima N
        • Maeda M
        • Umino M
        • Suzawa N
        • Yamada T
        • Takeda K
        Relation between FDG uptake and apparent diffusion coefficients in glioma and malignant lymphoma.
        Ann Nucl Med. 2012; 26: 262-271
        • Toh CH
        • Wei KC
        • Chang CN
        • Ng SH
        • Wong HF
        Differentiation of primary central nervous system lymphomas and glioblastomas: comparisons of diagnostic performance of dynamic susceptibility contrast-enhanced perfusion MR imaging without and with contrast-leakage correction.
        AJNR Am J Neuroradiol. 2013; 34: 1145-1149
        • Boxerman JL
        • Schmainda KM
        • Weisskoff RM
        Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not.
        AJNR Am J Neuroradiol. 2006; 27: 859-867
        • Ellingson BM
        • Kim HJ
        • Woodworth DC
        • Pope WB
        • Cloughesy JN
        • Harris RJ
        • Lai A
        • Nghiemphu PL
        • Cloughesy TF
        Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.
        Radiology. 2014; 271: 200-210
        • Huang LK
        • Wang MJJ
        Image thresholding by minimizing the measures of fuzziness.
        Pattern Recogn. 1995; 28: 41-51
        • Chu HH
        • Choi SH
        • Ryoo I
        • Kim SC
        • Yeom JA
        • Shin H
        • Jung SC
        • Lee AL
        • Yoon TJ
        • Kim TM
        • Lee SH
        • Park CK
        • Kim JH
        • Sohn CH
        • Park SH
        • Kim IH
        Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.
        Radiology. 2013; 269: 831-840
        • Rosenfeld SS
        • Hoffman JM
        • Coleman RE
        • Glantz MJ
        • Hanson MW
        • Schold SC
        Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography.
        J Nucl Med. 1992; 33: 532-536
        • Benard F
        • Romsa J
        • Hustinx R
        Imaging gliomas with positron emission tomography and single-photon emission computed tomography.
        Semin Nucl Med. 2003; 33: 148-162
        • Koeller KK
        • Smirniotopoulos JG
        • Jones RV
        Primary central nervous system lymphoma: radiologic–pathologic correlation.
        Radiographics. 1997; 17: 1497-1526
        • Kadoch C
        • Treseler P
        • Rubenstein JL
        Molecular pathogenesis of primary central nervous system lymphoma.
        Neurosurg Focus. 2006; 21: E1-E5
        • Louis DN
        • Ohgaki H
        • Wiestler OD
        • Cavenee WK
        Malignant lymphomas.
        in: Deckert M Paulus W WHO classification of tumours of the central nervous system. 4th ed. IARC Press, Lyon, France2007: 188-192
        • Molnar PP
        • O'Neill BP
        • Scheithauer BW
        • Groothuis DR
        The blood–brain barrier in primary CNS lymphomas: ultrastructural evidence of endothelial cell death.
        Neuro-Oncology. 1999; 1: 89-100
        • Watanabe M
        • Tanaka R
        • Takeda N
        • Wakabayashi K
        • Takahashi H
        Correlation of computed tomography with the histopathology of primary malignant lymphoma of the brain.
        Neuroradiology. 1992; 34: 36-42
        • Wesseling P
        • Ruiter DJ
        • Burger PC
        Angiogenesis in brain tumors; pathobiological and clinical aspects.
        J Neuro-Oncol. 1997; 32: 253-265
        • Willats L
        • Calamante F
        The 39 steps: evading error and deciphering the secrets for accurate dynamic susceptibility contrast MRI.
        NMR Biomed. 2013; 26: 913-931